<DOC>
	<DOC>NCT01728285</DOC>
	<brief_summary>Adherence to treatment is crucial to the efficacy of sublingual immunotherapy of allergic diseases. GRAZAX® is a registered drug in Europe, with established efficacy in the treatment of allergic rhinitis, which has to be taken daily by patients. This study was aimed to establish if a device with the characteristics of a mechanical dispenser (Memozax®) could improve adherence to treatment in subjects with hay fever due to allergy to grass</brief_summary>
	<brief_title>Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>A clinical history of grass polleninduced allergic rhinoconjunctivitis (with or without asthma) having received treatment during the previous grass pollen season. Positive skin prick test (SPT) response (wheal diameter ≥3mm) to Phleum pratense Positive specific IgE against Phleum pratense (IgE titer &gt; class 2) Clinical history of chronic sinusitis during the last 2 years or of symptomatic perennial or seasonal allergic rhinitis and/or asthma having received regular medication, due to another allergen during or potentially overlapping the grass pollen season. Clinical history of severe asthma (GINA Step 4 and children with Forced Expiratory Volume in 1 second (FEV1) &lt; 80% of expected value after treatment with inhaled corticosteroids and shortacting β2 agonists) Previous treatment by immunotherapy with grass pollen allergen or any other allergen within the previous 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>specific allergen immunotherapy</keyword>
	<keyword>sublingual immunotherapy</keyword>
	<keyword>allergen tablets</keyword>
	<keyword>compliance</keyword>
	<keyword>electronic compliance device</keyword>
</DOC>